SCHEMBL12018166

SCHEMBL12018166

Cc1cc2c(Oc3ccc(NC(=O)c4c(C)n(C)n(-c5ccccc5)c4=O)cc3F)ccnc2cc1OCC(C)(C)O

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 20/20 0.88
KDR P35968 15/20 0.88
AXL P30530 3/20 0.88
IGF1R P08069 12/20 0.82
INSR P06213 3/20 0.79
MST1R Q04912 2/20 0.79
AURKA O14965 1/20 0.79
JAK2 O60674 1/20 0.79
RPS6KA5 O75582 1/20 0.79
ABL1 P00519 1/20 0.79
LCK P06239 1/20 0.79
RET P07949 1/20 0.79
KIT P10721 1/20 0.79
PIM1 P11309 1/20 0.79
FGFR1 P11362 1/20 0.79
SRC P12931 1/20 0.79
PRKACA P17612 1/20 0.79
RPS6KB1 P23443 1/20 0.79
JAK1 P23458 1/20 0.79
MAPK3 P27361 1/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12004355 0.94 MET (1.00) METKDRAXLIGF1RINSR
Ningetinib SCHEMBL29392305 0.91 MET (1.00) METKDRAXLIGF1RINSR
Ningetinib SCHEMBL12003786 0.91 MET (1.00) METKDRAXLIGF1RINSR
Ningetinib SCHEMBL29366570 0.91 MET (1.00) METKDRAXLIGF1RINSR
SCHEMBL12018173 0.91 MET (0.85) METKDRAXLIGF1RINSR
Ningetinib SCHEMBL12003712 0.90 MET (0.99) METKDRAXLIGF1RINSR
SCHEMBL12018170 0.88 MET (0.90) METKDRAXLIGF1RINSR
SCHEMBL17081124 0.88 MET (0.90) METKDRAXLIGF1RINSR
Ningetinib SCHEMBL12004019 0.88 MET (0.93) METKDRAXLIGF1RINSR
Ningetinib SCHEMBL12004022 0.88 MET (0.93) METKDRAXLIGF1RINSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9598400-B2 Substituted quinoline compounds and methods of use CALITOR SCIENCES, LLC (US) 2017-03-21 US disclosed
US-20150342945-A1 SUBSTITUTED QUINOLINE COMPOUNDS AND METHODS OF USE CALITOR SCIENCES, LLC (US) 2015-12-03 US disclosed
US-9133162-B2 Substituted quinoline compounds and methods of use SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-09-15 US disclosed
US-20120219522-A1 SUBSTITUTED QUINOLINE COMPOUNDS AND METHODS OF USE XI, Dr. Ning (US) 2012-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150342945-A1 SUBSTITUTED QUINOLINE COMPOUNDS AND METHODS OF USE MKI67, MCL1, NRAS MET 997/4885KDR 577/4885AXL 1395/4885
US-20120219522-A1 SUBSTITUTED QUINOLINE COMPOUNDS AND METHODS OF USE MKI67, MCL1, NRAS MET 997/4885KDR 577/4885AXL 1395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.